Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IMNX slides pre-NASDAQ 100 shuffle

Immunex (IMNX) fell $2.56 (13%) to $16.99 on 50.6 million shares on Monday, one day prior to its planned exit from the NASDAQ 100 Index (NDX). Investors who want

Read the full 292 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE